Table 2.
Main survey findings stratified by participant designation (N=151).
| Survey findings | Participant designation | P valuea | ||||
| Physicians (n=64) | Nursesb (n=79) | Othersc (n=8) |
|
|||
|
Responder characteristics
| ||||||
|
|
Sex (males), n (%) | 27 (42.2) | 9 (11.4) | 1 (12.5) | .001 | |
|
|
Age (years), median (IQR) | 41 (31-51) | 37 (29-46) | 46 (31-56) | .14 | |
| Knowledge of COVID-19, n (%) | .001 | |||||
|
|
Expert | 39 (60.9) | 16 (20.2) | 1 (12.5) |
|
|
|
|
Basic | 25 (39.1) | 55 (69.6) | 7 (87.5) |
|
|
|
|
Some | 0 (0) | 7 (8.9) | 0 (0) |
|
|
|
|
No knowledge | 0 (0) | 1 (1.3) | 0 (0) |
|
|
| Site of work, n (%) | .01 | |||||
|
|
Emergency department | 8 (12.5) | 16 (20.3) | 6 (75.0) |
|
|
|
|
Intensive care units | 4 (6.3) | 18 (22.8) | 1 (12.5) |
|
|
|
|
Hospitalization wards | 31 (48.4) | 26 (32.9) | 1 (12.5) |
|
|
|
|
External offices/other | 21 (32.8) | 19 (24.0) | 0 (0) |
|
|
| Main motivators, n (%) | .03 | |||||
|
|
Scientific knowledge | 31 (48.5) | 42 (53.2) | 7 (87.5) |
|
|
|
|
To prevent SARS-CoV-2 infection | 13 (20.3) | 20 (25.3) | 0 (0) |
|
|
|
|
To have access to a SARS-CoV-2 rapid test | 18 (28.1) | 9 (11.4) | 1 (12.5) |
|
|
|
|
Other | 2 (3.1) | 8 (10.1) | 0 (0) |
|
|
| MeCOVID trial participants, n | 62 | 77 | 8 |
|
||
| Reason to participate in the MeCOVID trial (multiple answer question), n (%) | <.001 | |||||
|
|
Adverse reactions to drugs in the EPICOS trial | 53 (85.5) | 49 (63.6) | 0 (0) |
|
|
|
|
Melatonin being a sleep aid | 6 (9.7) | 17 (22.1) | 1 (12.5) |
|
|
|
|
Melatonin having a high efficacy | 2 (3.2) | 17 (22.1) | 6 (75.0) |
|
|
|
|
Contraindications regarding EPICOS drugs | 1 (1.6) | 4 (5.2) | 0 (0) |
|
|
|
|
Not reported | 4 (6.5) | 1 (1.3) | 1 (12.5) |
|
|
| Expectations regarding the MeCOVID trial, n (%) | .13 | |||||
|
|
Drug efficacy and safety | 26 (42.0) | 50 (64.9) | 8 (100) |
|
|
|
|
Drug efficacy with adverse reactions | 2 (3.2) | 14 (18.2) | 0 (0) |
|
|
|
|
No drug efficacy and no adverse reactions | 31 (50.0) | 13 (16.9) | 0 (0) |
|
|
|
|
No drug efficacy with adverse reactions | 1 (1.6) | 0 (0) | 0 (0) |
|
|
|
|
Not reported | 2 (3.2) | 0 (0) | 0 (0) |
|
|
aP values refer to differences between the responses of physicians and nurses. “Others” have been excluded from the analysis owing to their small sample size.
b“Nurses” includes nurse practitioners (n=54) and nursing assistants (n=25).
c“Others” includes laboratory technicians (n=2) and ancillary personnel (n=6).